Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer by Vignani, Francesca et al.
This full text was downloaded from iris - AperTO: https://iris.unito.it/
iris - AperTO
University of Turin’s Institutional Research Information System and Open Access Institutional Repository
This Accepted Author Manuscript (AAM) is copyrighted and published by Elsevier. It is
posted here by agreement between Elsevier and the University of Turin. Changes resulting
from the publishing process - such as editing, corrections, structural formatting, and other
quality control mechanisms - may not be reflected in this version of the text. The definitive
version of the text was subsequently published in CANCER TREATMENT REVIEWS,
44, 2016, 10.1016/j.ctrv.2016.02.002.
You may download, copy and otherwise use the AAM for non-commercial purposes
provided that your license is limited by the following restrictions:
(1) You may use this AAM for non-commercial purposes only under the terms of the
CC-BY-NC-ND license.
(2) The integrity of the work and identification of the author, copyright owner, and
publisher must be preserved in any copy.
(3) You must attribute this AAM in the following format: Creative Commons BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en),
10.1016/j.ctrv.2016.02.002
The publisher's version is available at:
http://linkinghub.elsevier.com/retrieve/pii/S0305737216000177
When citing, please refer to the published version.
Link to this full text:
http://hdl.handle.net/2318/1615145
1 
 
 Skeletal metastases and impact of anticancer and bone-targeted agents in patients 
with castration-resistant prostate cancer 
Francesca Vignani*a, Valentina Bertaglia*a, Consuelo Buttigliero a, Marcello Tucci a, Giorgio V. 
Scagliotti a, Massimo Di Maio a.  
 
* These Authors equally contributed to the review 
 
a Division of Medical Oncology, Department of Oncology, University of Turin at San Luigi Gonzaga 
Hospital, Orbassano, Turin, Italy  
  
 
 
 
 
Corresponding Author: Marcello Tucci, MD  
Division of Medical Oncology, Department of Oncology, University of Turin, San Luigi Gonzaga 
Hospital, Regione Gonzole 10, 10043 Orbassano (Turin), Italy;  
Tel. +390119026414;  
Fax +390119015184; 
e-mail: marcello.tucci@gmail.com 
 
 
 
 
 
2 
 
Skeletal metastases and impact of anticancer and bone-targeted agents in patients 
with castration-resistant prostate cancer 
Skeletal metastases and impact of anticancer and bone-targeted agents in patients 
with castration-resistant prostate cancer 
3 
 
 ABSTRACT  
Incidence of bone metastases is very high in advanced prostate cancer patients. Bone 
metastases likely have a significant impact on functional status and quality of life, not only 
related to pain, but also to the relevant risk of skeletal-related events. A better 
understanding of mechanisms associated with bone metastatic disease secondary to 
prostate cancer and more specifically to the cross-talk between tumor cells and bone 
microenvironment in metastatic progression represented the background for the 
development of new effective bone-targeted therapies. Furthermore, a better knowledge of 
biological mechanisms driving disease progression led to significant advances in the 
treatment of castration-resistant prostate cancer, with the development and approval of 
new effective drugs. Aim of this review is to outline the physiopathology of bone 
metastases in prostate cancer and summarize the main results of clinical trials conducted 
with different drugs to control morbidity induced by skeletal metastases and bone disease 
progression. For each agent, therapeutic effect on bone metastases has been measured 
in terms of pain control and/or incidence of skeletal-related events, usually defined as a 
composite endpoint, including the need for local treatment (radiation therapy or surgery), 
spinal cord compression, pathological bone fractures. In details, data obtained with 
chemotherapy (mitoxantrone, docetaxel, cabazitaxel), new generation hormonal agents 
(abiraterone, enzalutamide), radium-223, bone-targeted agents (zoledronic acid, 
denosumab) and with several experimental agents (cabozantinib, dasatinib, anti-
endothelin and other agents) in patients with castration-resistant prostate cancer  are 
reviewed. 
KEYWORDS 
Castration resistant prostate cancer, bone metastasis, skeletal related event, new 
generation hormonal agents, chemotherapy, bone-targeted therapy  
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INTRODUCTION 
In developed countries, prostate cancer is the most common type of cancer diagnosed 
among men, with more than 1,100,000 new cases worldwide every year [1]. In this cancer, 
bone represents a preferential site of metastases, and patients with advanced disease 
have a very high incidence of bone metastases [2]. Autopsy data from prostate cancer 
patients indicate an incidence of secondary bone lesions as high as 65%-75%, preceded 
only by multiple myeloma [3]. These bone metastases are typically osteosclerotic (i.e. with 
increased osteoblastic activity), and likely to produce a significant impact on patients’ 
functional status and quality of life (QoL), not only related to pain, but also to the relevant 
risk of skeletal-related events (SREs) that can negatively impact physical well-being and 
activities of daily living [4,5]. According to Food and Drug Administration [6], skeletal 
related events (SREs) include pathologic bone fractures (both vertebral and non-
vertebral), spinal cord compression, surgery to bone, radiotherapy to bone. To estimate 
the incidence of SREs in patients with prostate cancer and bone metastases the control 
arm of  the trials testing bisphosphonates may be used as a reference value [7]. In a 15-
month observation period, nearly half (44.2%) of those patients experienced at least one 
SRE.  
SREs may have a relevant impact on survival of prostate cancer patients with bone 
metastases. In a landmark analysis of a randomized trial comparing zoledronic acid (ZA) 
versus placebo, patients without SREs in the first six months had significantly better 1-year 
survival rate compared to patients suffering from one or more SRE [8]. Furthermore, 
survival of patients with multiple events was worse than propensity-matched patients with 
only one SRE, although this difference was not statistically significant. A secondary 
analysis of randomized trials with ZA showed that, in patients with metastatic prostate 
cancer similarly to other tumor types, the incidence of pathological fractures is associated 
with a significantly increased risk of death [7]. In details, patients with pathological 
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fractures had a 29% increase in the risk of death at the unadjusted analysis (Hazard Ratio 
[HR] 1.29, 95% confidence interval [CI] 1.01-1.65), with comparable results observed for 
both vertebral and non-vertebral fractures. Adjusted analyses for prognostic covariates, 
including previous SRE occurrence and performance status, led to comparable results. As 
expected, although prostate cancer patients with metastatic spinal cord compression had a 
relatively better life expectancy compared to other tumors, this complication has a relevant 
impact on survival [9,10].  
Patients with a SRE have a significantly worse QoL [5,8] and  when assessed by validated 
instruments, such as the Functional Assessment of Cancer Therapy-General (FACT-G) 
and the Brief Pain Inventory (BPI), a clearly worse outcome was observed in patients with 
SREs compared to those without, with statistically significant differences in FACT-G total 
score, in functional well-being, physical well-being, emotional well-being and in BPI score 
[8]. When all types of SRE were considered as a whole (need for radiation, pathological 
fractures, other SRE) there was a statistically significant and clinically relevant decline in 
QoL in all domains [5]. Of course, treatment of SRE can improve QoL: radiation therapy 
can produce a significant reduction of pain [5], while treatment of spinal cord compression 
may improve performance status [10]. The occurrence of bone complications is also likely 
be responsible of the increased  direct and indirect costs of patients’ management [11]. 
All SREs are associated with relevant health resource utilization, including both inpatient 
hospitalizations and outpatient or emergency department visits and procedures [12-14]. 
Furthermore, those studies trying to calculate the costs associated with SREs may have 
under-estimated their global impact in terms of health resource utilization, due to the 
exclusion of patients with low performance status or life expectancy, and the exclusion of 
resource consumption associated with bone pain management [15].  
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Recently, the management of castration-resistant prostate cancer (CRPC) significantly 
changed, with approval of several new drugs [16]. This evolving therapeutic landscape 
was paired by a better knowledge of biological mechanisms driving disease progression. 
Nowadays, we know that AR signalling pathway has a significant activity also in CRPC 
and that the interplay between prostate cancer cells and bone microenvironment plays a 
crucial role in bone metastatic progression. 
Aim of this review is to outline the physiopathology of bone metastases in prostate cancer 
and the contribution of each of these new agents in terms of control of morbidity induced 
by skeletal metastases and bone disease progression. 
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PHYSIOPATHOLOGY OF BONE METASTASES IN PROSTATE CANCER 
Bone metastasis is a complex event due to the interaction among cancer cells, normal 
bone cells and bone microenvironment, leading to a severe disruption of physiological 
bone remodeling [17]. The latter is a dynamic process, critical to maintain skeletal integrity, 
responsible for replacement of old bone with a mechanically more competent bone. It 
occurs at specialized skeleton sites - called “bone remodeling units” - and is characterized 
by a functional sequence: osteoclast-mediated bone resorption followed by osteoblast-
induced bone apposition [18,19].  
In the early phase of bone remodeling, osteoclasts are attracted to bone surface, in which 
these cells excavate the Howship’s lacuna, a resorption cavity. Following the cavity 
formation, osteoclasts produce several factors responsible for osteoblasts attraction to the 
sites of previous resorption. This sequence of events is called “coupling phenomenon”. As 
described by Paget in 1889, tumor cells are “the seeds” which need a favorable “soil” in 
order to thrive at metastatic sites [20]. Skeletal microenvironment is an ideal “soil”, due to 
presence of growth factors and cytokines stored in the bone matrix and released during 
cross-talk between bone-resident cells and cancer cells [21].  
In the metastatic cascade, the first step is the homing of tumor cells to skeletal tissue 
[21,22]. This process is not a casual event, but is due to the production by bone 
microenvironment of the same chemotactic factors responsible for the migration of 
hematopoietic stem cells into the bone marrow. These cells are localized at a specific site, 
the hematopoietic stem cell niche, where they may remain quiescent or divide and then 
differentiate. An important chemotactic factor is the stromal-derived factor-1 (SDF-1), also 
called CXCL12. This cytokine, mainly produced by osteoblasts, interacts with the CXCR4 
receptor on hematopoietic stem cells, inducing their homing to the bone marrow [21-24]. 
The pathway SDF-1/CXCR4 is also able to modulate the attraction of prostatic tumor cells 
to bone. Some preclinical studies showed a significant expression of CXCR4 on the 
8 
 
surface of prostate cancer cells [25]. The induction of SDF-1 expression from bone marrow 
endothelial cells favors prostatic cancer migration and adhesion to extracellular bone 
matrix [22,26]. Therefore, prostatic tumor cells are able to compete with hematopoietic 
stem cells for the place in the bone marrow niche; this complex process determines the 
formation of so-called “onco-niche”, in which cancer cell may remain in a state of 
dormancy or may start to colonize and invade (Figure A) [17,21,22].  
During the metastatic colonization of the bone, prostate cancer cells interfere with the 
physiological bone remodeling due to the release of paracrine factors physiologically 
involved in the regulation of both osteoclastic and osteoblastic activity (Figure B). The 
early, crucial phase of this process is the abnormal increase of osteoclast-mediated bone 
resorption, due to several growth factors and cytokines, as transforming growth factor β1 
(TGF β1), parathyroid-hormone-related peptide and interleukin 6 [27]. These factors lead 
to the activation of the receptor activator nuclear kappa B (RANK) / RANK ligand (RANKL) 
pathway, which plays a central role in bone resorption regulation. RANKL, produced by 
osteoblasts, binds its receptor RANK on osteoclasts surface, favoring osteoclast 
maturation, survival and activity [17,21]. Increased osteolysis is crucial for the seeding of 
prostate cancer cells, and is also associated with the release from the bone matrix of 
several growth and survival factors, responsible for tumor progression [27]. In the 
subsequent phase of skeletal colonization there is an excessive bone apposition, which 
becomes dominant compared to bone resorption. This is due to growth factors including 
basic fibroblast growth factor, bone morphogenic proteins, endothelin-1 (ET-1), tumour 
growth factor 1 and insulin-like growth factor 1, that are released by cancer cells and from 
bone matrix and stimulate both osteoblasts activity and tumor proliferation. Prostatic 
cancer cells may also contribute to bone apposition by gaining the same functional 
activities of osteoblasts (“osteomimicry”) [27].  
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The complex interaction between bone microenvironment and tumor cells leads to the so-
called “vicious cycle”, that induces cancer progression [17].  
Prostate cancer patients with bone metastases frequently have SREs due to increased 
osteolysis in typically osteoblastic bone lesions [17,28]. Increased osteoclastic activity is 
not only confined to metastatic sites, but it may be considered a more generalized event 
[17,28]. This is caused by secondary hyperparathyroidism, due to the so-called “bone 
hunger syndrome”, a metabolic derangement in which calcium entrapment in skeletal 
tissue, due to increased osteoblastic activity, leads to hyperparathyroidism in response to 
serum calcium deficiency [29]. Compensatory increase of parathyroid hormone secretion 
is responsible of osteoclasts activation at distant sites.  
Furthermore, an additional cause of bone resorption is represented by iatrogenic 
osteoporosis, induced by androgen deprivation treatment [28]. 
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Skeletal related events: different definitions. 
In older trials, therapeutic effect on bone metastases was measured in terms of pain, 
decrease in biochemical markers of bone turnover, serial imaging assessment showing 
healing of bone lesions [30]. In recent trials, SREs have been defined as a composite 
endpoint, mostly including the need for local treatment (radiotherapy or surgery), spinal 
cord compression and pathological bone fractures [31-36]. Radiotherapy may include 
treatment of uncontrolled pain, treatment or prevention of imminent pathologic fractures, 
treatment or prevention of spinal cord compression. Surgery may include procedures to 
stabilize pathologic fractures or spinal cord compression, but also procedures aimed to 
prevent these SREs. Some trials consider only skeletal symptomatic events (SSE), other 
trials include also asymptomatic bone fractures. Only in some trials the use of 
radioisotopes is explicitly included among the radiation therapy procedures. Table A 
summarizes the definition of SREs in selected randomized trials conducted in patients with 
metastatic prostate cancer, using SREs as primary or secondary endpoint.    
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IMPACT OF ANTI-CANCER TREATMENTS 
Chemotherapy 
Mitoxantrone  -  
At the beginning of this century, mitoxantrone plus prednisone was commonly used in 
CRPC patients for its palliative role, despite the negative outcome of randomized trials that 
did not show a significant improvement in overall survival (OS) [37,38]. In one trial CRPC 
patients with pain received mitoxantrone plus prednisone or prednisone alone (Table B) 
[37]. Most of the enrolled patients (96%) had bone metastases. The primary endpoint was 
palliative response, defined as pain decrease without an increase in analgesics use. 
Palliative response rate was 29% with mitoxantrone plus prednisone and 12% with 
prednisone alone (p=0.01). Decrease in analgesics use without an increase in pain, one of 
the secondary endpoints, was comparable in the two arms. Later, another trial compared 
hydrocortisone alone vs. hydrocortisone plus mitoxantrone (Table B) [38]. Although there 
was no significant OS benefit, which was the primary endpoint, frequency and severity of 
pain were significantly better with mitoxantrone. Unfortunately, none of the trials included a 
description of SREs.  
 
Docetaxel -  
Before the TAX-327 [39] and the SWOG 99-16 study [40], that demonstrated the efficacy 
of docetaxel, no OS benefit had been shown with chemotherapy in CRPC patients. Both 
those two trials had OS as primary endpoint, while the impact on pain was among 
secondary endpoints (Table B). TAX-327 study compared two docetaxel schedules 
(every-3-week or weekly) plus prednisone versus mitoxantrone plus prednisone, and 
showed a significant OS benefit with every-3-week docetaxel [39,41]. Most patients (91%) 
had bone metastases and 45% had baseline pain. A reduction in pain was more frequently 
documented with every-3-week docetaxel than with mitoxantrone [39]. Pain response was 
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associated with OS outcome: median survival was 18.6 months among patients who 
achieved a pain response versus 12.5 months in patients who did not obtain pain 
response. However, improvement in median OS with every-3-week docetaxel was 3.9 
months among men without significant baseline pain, and 2.4 months among those with 
baseline pain, suggesting that OS benefit associated with docetaxel is not limited to 
symptomatic patients obtaining pain response [42,43]. In the SWOG 99-16 trial, patients 
were randomized to docetaxel plus estramustine versus mitoxantrone plus prednisone 
[40]. Patients in docetaxel-estramustine arm had a significant OS improvement, although 
pain relief was similar in the two arms. In both these randomized trials, no specific SREs 
description was available.  
Although not referred to CRPC but conducted in the “earlier” setting of hormone-naïve 
prostate cancer patients, in the STAMPEDE trial, the addition of docetaxel to androgen 
deprivation treatment (ADT) produced not only a relevant OS benefit (HR 0.78; p=0.006), 
but also a significant reduction in the time to first reported SSE (HR 0.60; p= 0.13 x 10-5) 
(Table B) [44]. 
  
Cabazitaxel -  
In preclinical and clinical models, cabazitaxel showed significant efficacy in docetaxel-
resistant and refractory prostate carcinomas [45,46]. In the randomized phase III TROPIC 
trial, comparing cabazitaxel plus prednisone versus mitoxantrone plus prednisone in 
patients with metastatic CRPC after docetaxel failure, cabazitaxel was associated with a 
significant prolongation of OS [47]. More than 80% of patients had bone metastases, and 
about 45% had baseline pain. Secondary endpoints included pain response and time to 
pain progression, and cabazitaxel showed similar pain improvement compared to 
mitoxantrone (Table B) [48]. In an expanded access program conducted in United 
Kingdom, 31%-57% of patients treated with cabazitaxel reported “no pain or discomfort” 
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during treatment at various cycles, compared to 22% at baseline [49]. No specific 
description of the impact on SREs of cabazitaxel is available.
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New generation hormonal agents 
Abiraterone -  
Abiraterone acetate (AA) is a potent, selective and irreversible inhibitor of CYP17, a critical 
enzyme in androgens synthesis [50]. The randomized trial COU-AA-301 compared AA 
plus prednisone vs. placebo plus prednisone in patients with metastatic CRPC (mCRPC) 
progressing after chemotherapy [51]. AA plus prednisone demonstrated a significant 
survival benefit [51,52]. At baseline, about 90% of patients in both arms had bone 
metastases, with similar pain scores. Incidence of SREs was 29% with AA and 33% with 
placebo; time to first SRE was significantly longer with AA (median 25.0 vs. 20.3 months; 
HR 0.615; p=0.0001) [35] (Table B). The most common SRE (expressed as rate per 100 
patients-years of exposure) was bone radiation (24% with AA vs. 46.1% with placebo); 
others included pathologic fracture (6.0% vs. 4.0%), bone surgery (1.7% vs. 1.0%), and 
spinal cord compression (7.3% vs. 14.0%). In patients with clinically significant pain at 
baseline, AA produced significantly more palliation (45.0% vs. 28.8%; p=0.0005) and 
faster palliation of pain intensity (median time to palliation 5.6 vs. 13.7 months; p=0.0018) 
[35]. Iuliani and al. investigated AA activity on bone microenvironment in an in vitro model 
and in a clinical prospective cohort of 49 mCRPC patients, in which serum markers of 
bone turnover (ALP and CTX) were measured at baseline and every 3 months during 
treatment with AA [53]. AA was associated with a statistically significant inhibition of 
osteoclast differentiation and with osteoblasts differentiation. During treatment, patients 
had a progressive CTX reduction along with an increase of ALP values. In conclusion, this 
study demonstrated a direct bone anabolic and anti-resorptive effect of AA.  
The randomized trial COU-AA-302 evaluated AA with prednisone compared to placebo 
plus prednisone in asymptomatic or mildly symptomatic mCRPC docetaxel-naive patients 
(Table B) [54]. Co-primary endpoints included radiographic progression-free survival 
(rPFS) and OS. The proportion of patients with bone disease only (51% and 49% in 
15 
 
experimental and control arm, respectively), and that of patients with more than 10 bone 
lesions (49% and 47%, respectively), were similar in the two arms. AA improved both OS 
and rPFS. Furthermore, secondary endpoints, such as time to symptomatic deterioration, 
time to pain progression and PSA PFS were significantly improved. Treatment with AA 
was associated with a significant improvement in time to opiate use (median not reached 
vs. 23.7 months; p=0.001), in time to increase in pain (median 26.7 vs. 18.4 months, 
p=0.049), and in time to progression of pain interference (median 10.3 vs. 7.4 months; 
p=0.005). Unfortunately, no data are available about the impact of treatments on SREs 
occurrence. A post hoc analysis evaluated the safety and efficacy of AA with concomitant 
bone targeted therapies (BTT) [55]. Overall, 34% of patients in experimental arm and 31% 
in control arm received concomitant BTT. Superiority of AA was confirmed both with and 
without BTT. Furthermore, although the interpretation of these results is limited by their 
post hoc nature, concomitant BTT prolonged time to opioid use (HR 0.80; p=0.036), time 
to performance status deterioration (HR 0.75; p<0.001) and was associated with better OS 
(HR 0.75; p=0.01). In a retrospective study of mCRPC patients treated with AA, out of 123 
patients with baseline pain, 29% reported an improvement during treatment, 32% no 
change and 28% a worsening [56].  
 
Enzalutamide -  
Enzalutamide is an AR antagonist, more potent than first-generation drugs [57]. Similarly 
to abiraterone, enzalutamide is approved for the treatment of both patients with mCRPC 
progressing after chemotherapy and chemotherapy-naive patients. The AFFIRM phase III 
trial randomized men with mCRPC progressing after chemotherapy to enzalutamide 
versus placebo (Table B) [58]. At baseline, proportion of patients with bone lesions (about 
92%), proportion of patients with more than 20 lesions (38%), and intensity of pain were 
similar between arms. Enzalutamide demonstrated a significant improvement in OS which 
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was the primary end point of the study, and its superiority was confirmed in all secondary 
endpoints. In details, median time to first SRE was 16.7 months with enzalutamide versus 
13.3 months with placebo (HR 0.69; p<0.001) (Table B) [34]. Approximately half of 
patients were receiving a bisphosphonate at baseline. Time to first SRE was significantly 
improved by enzalutamide in patients not receiving bisphosphonate (HR 0.614; p=0.0005) 
and not significantly in patients who were receiving bisphosphonate (HR 0.762; p=0.553), 
although the study was not designed and powered to test this interaction. Enzalutamide 
provided consistent benefits in several pain measures, including pain severity, pain 
interference and pain palliation. Pain palliation was achieved in 45% of patients with 
enzalutamide versus 7% with placebo (p=0.0079).   
The phase III PREVAIL study compared enzalutamide versus placebo in asymptomatic or 
mildly symptomatic patients with chemotherapy-naïve mCRPC (Table B), having OS and 
rPFS as co-primary endpoints [59]. Both were significantly improved with enzalutamide. At 
baseline, number of bone lesions and pain intensity were similar between arms. Although 
median time to first SRE was similar in the two arms, the risk of first SRE was significantly 
decreased with enzalutamide (HR 0.72; 95%CI 0.61-0.84; p<0.001) (Table B) [60]. 
Median time to pain progression was 5.7 months with enzalutamide versus 5.6 months 
with placebo (HR 0.62, 95%CI 0.53-0.74; p<0.0001). At week 13, progression of pain was 
significantly less common with enzalutamide (29%) than with placebo (42%, p<0.0001).  
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Radium-223 - 
Radium-223 dichloride is a  particle-emitting agent [61] and, as a calcium mimetic, is 
taken up into areas of high bone turnover, such as bone metastases [62]. Once radium-
223 binds bone,  particles induce double-stranded DNA breaks, causing a local citotoxic 
effect [63]. To date, it is the only radionuclide that showed OS benefit in CRPC. The phase 
III trial ALSYMPCA randomized mCRPC patients with bone metastases and without 
visceral metastases to receive either radium-223 or placebo in addition to the best 
standard of care (Table C) [64], having OS as the primary endpoint.  Time to first SSE and 
time to increase in alkaline phosphatase (ALP) were among secondary endpoints. At 
baseline, number of bone lesions and pain intensity were similar between the arms. OS 
was significantly prolonged by radium-223  and time to first SSE was also improved 
(median 15.6 vs. 9.8 months; HR 0.66, 95%CI 0.52-0.83; p<0.001). The use of external 
beam radiation therapy to treat bone pain and the risk of spinal cord compression were 
significantly reduced, while radium-223 did not significantly reduce the risk of symptomatic 
pathological bone fracture and the need for tumor-related surgery. Decrease in ALP ≥30% 
occurred in 47% with radium-223 vs. 3% with placebo (p<0.001) [36]. Radium-223 
provided a delay in biochemical (ALP) progression (median 7.4 vs. 3.8 months). In the 
ALSYMPCA study, 55% of patients required opioids at baseline [65]. Data about pain 
response were not collected, however in patients without opioids at baseline the proportion 
of patients who received opioids during study was 36% with radium-223 versus 50% with 
placebo, and radium-223 significantly delayed time to opioids use (HR 0.62; 95%CI 0.46–
0.85). At baseline, 41% of patients were treated with BTT, and radium-223 increased OS 
regardless of bisphosphonate use. Delay in SSEs with radium-223 was reported both in 
patients not treated with BTT (although not statistically significant: median 11.8 vs. 8.4 
months; HR 0.77; p=0.07) and in patients treated with bisphosphonates (median 19.6 vs. 
10.2 months; HR 0.49; p=0.00048). In 2015, a systematic review evaluated the efficacy of 
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radiopharmaceuticals (89-strontium-chloride, 153-samarium-EDTMP, 186-rhenium-HEDP, 
188-rhenium-HEDP and 223-radium-chloride) for palliation of bone pain from prostate 
cancer [66]. Pain response rates greater than 50%–60% were observed with all 
radionuclides. However, this review did not identify which radionuclide provides the best 
level and duration of pain relief, and OS results are not easily interpreted, because most 
studies were underpowered.  
19 
 
Bone-targeted agents 
Zoledronic acid and other bisphosphonates–  
Bisphosphonates reduce excessive bone turnover while preserving bone structure and 
mineralization. In early 1990s, several trials were initiated to investigate the use of 
bisphosfonates in prostate cancer: PR04 trial investigated the efficacy of sodium 
clodronate in locally advanced PC with negative bone scan, while PR05 investigated the 
same compound in bone metastatic hormone sensitive patient [67, 68]. Both trials resulted 
negative in terms of bone metastases- free survival and symptomatic bone PFS 
advantage, respectively. Mature data about OS, that was secondary endpoint, were 
published later: these data showed a benefit in OS only in PR05 patients, not in PR04 
patients [69]. 
The first agent approved for the management of bone metastases in CRPC patients was 
zoledronic acid (ZA), a third-generation bisphosphonate. A phase III trial compared ZA 
versus placebo, demonstrating a significant reduction in the incidence of at least one SRE 
during the 24-month study period (Table C) [31,70]. Proportion of patients with at least one 
SRE was 49% with placebo and 38% with ZA (p=0.028). Furthermore, ZA significantly 
prolonged time to first SRE (HR 0.67; p=0.009), and time to first and subsequent SRE (HR 
0.64, p= 0.002). The annual SRE incidence was 0.77 with ZA versus 1.47 with placebo 
(p=0.005 ) [71]. Pain scores and use of analgesics favored ZA. There were no differences 
either in disease progression or in OS [31,70]. In this study, 70% of patients treated with 
ZA had normalization within 1 month of the urinary levels of N-telopeptide (NTX), a 
markers of bone resorption. The normalization of NTX levels within 3 months correlated 
with a 59% reduction in the risk of death (p<0.0001) [71]. 
The TRAPEZE trial investigated the efficacy of addition of ZA and/or strontium-89 to 
docetaxel in CRPC patients [72]. Patients were randomized to receive docetaxel plus 
prednisolone: alone; with ZA; with a single dose of Sr89 after cycle 6 or both. Sr89 
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improved clinical progression free survival (CPFS), but not OS. ZA did not improve CPFS 
or OS but did significantly improve median SRE-free interval, mostly post-progression, 
suggesting a role as post-chemotherapy maintenance therapy. (Table C) 
Of note, several trials have tested the role of zoledronic acid in patients with “earlier” 
phase of disease. The CALGB90202 study randomized castration-sensitive prostate 
cancer patients to ZA or placebo, with the aim of detecting a  reduction in the risk of first 
SRE (Table C) [73]. Unfortunately, the primary endpoint was not met. Early treatment with 
ZA was not associated with a decreased SRE risk, compared with treatment initiation after 
progression to castration-resistant disease. Similarly, in the abovementioned STAMPEDE 
trial (Table B), the addition of ZA to ADT in hormone-naïve patients did not translate into a 
significant benefit in time to first SSE, both in the entire population and in the subgroup of 
patients with bone metastases [44]. On the contrary, the arm testing the addition of both 
docetaxel and ZA to ADT produced a significant benefit, but similar to the benefit obtained 
with docetaxel alone. 
The ZEUS study investigated the efficacy of ZA for the prevention of bone metastasis in 
high-risk non-metastatic prostate cancer patients receiving ADT [74]: there was no 
difference in the occurrence of bone metastasis. After a median follow-up of 4.8 years, the 
proportion of bone metastasis was 14.7% with ZA and 13.2% in control group (p=0.65). 
In conclusion, data about a post hoc analysis of RADAR trial, conducted in patients with 
locally advanced prostate cancer, must be mentioned but regarded cautiously [75]. 
RADAR trial investigated whether 18 months of androgen suppression (intermediate-term 
androgen suppression, ITAS) plus radiotherapy with or without 18 months of ZA is more 
effective than 6 months of neoadjuvant androgen suppression (short-term androgen 
suppression, STAS) plus radiotherapy with or without ZA. Secondary endpoint data and 
post hoc analyses showed that ITAS plus ZA reduce PSA progression and decrease need 
for secondary therapeutic intervention, in patients with Gleason 8-10 tumors. However, 
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neither prostate cancer-specific mortality nor all-cause mortality differed between control 
and experimental groups. 
Considering this negative evidence in castration-sensitive and high-risk non metastatic 
prostate cancer patients, CRPC is the only setting of disease with proven efficacy of ZA in 
the management of bone metastases. 
 
Denosumab -  
Denosumab is a fully human monoclonal antibody against RANKL, and prevents the 
activation of its receptor, RANK, thus inhibiting osteoclast formation, function and survival, 
decreasing bone resorption and increasing bone mass and strength [32]. In a phase III trial 
that compared denosumab versus ZA in patients with bone metastatic CRPC, denosumab 
produced a 3.6 months significant improvement in median time to first SRE [32] (Table C). 
Furthermore, denosumab significantly delayed time to first and subsequent SREs (rate 
ratio 0.82, p=0.008). The two groups had a similar OS and time-to-disease progression. At 
week 13, median decrease in concentration of urinary N-telopeptide adjusted for creatinine 
(uNTX/Cr) and serum bone ALP were significantly greater with denosumab [32]. An 
exploratory analysis showed that, compared with ZA, denosumab significantly reduced 
also the risk of first SSE (HR 0.78, p=0.005) and first and subsequent SSEs (rate ratio 
0.78, p=0.004) [76]. 
Of note, similarly to ZA, denosumab has subsequently been also tested in non-metastatic 
patients to evaluate its efficacy in delaying time to bone metastases. In a phase III, 
placebo- controlled trial in non-metastatic CRPC patients at high risk for bone metastasis, 
denosumab generated a 4.2- month improvement in median bone metastasis-free survival 
(BMFS, HR 0.85, p=0.028), in contrast with above mentioned ZEUS trial results that, 
however, were obtained in hormone sensitive patients [77]. Denosumab also produced a 
33% reduction in the risk of symptomatic bone metastasis. However, there was no impact 
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on time to overall prostate cancer progression or OS (Table C) [77]. The relationship 
between both PSA value and PSA doubling time (PSADT) at baseline with BMFS was 
explored [78]. In the placebo group, patients with PSADT < 8 months had a shorter BMFS. 
Denosumab consistently increased BMFS among men with PSADT ≤10 months (HR 0.84; 
p=0.042), ≤6 months (HR 0.77; p=0.006) and ≤4 months (HR 0.71; p=0.004) [78]. 
Based on these results, beyond its efficacy in metastatic CRPC, denosumab has also 
shown a role in prolonging BMFS in high-risk non metastatic patients.   
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New drugs 
Several new drugs have been recently or are currently being tested in prostate cancer 
patients. Here we summarize the results reported in studies investigating cabozantinib, 
dasatinib, anti-endothelin drugs, cathepsin K inhibitors and aflibercept, with specific details 
about bone disease control, although all these drugs did not show any improvement of 
survival benefit in phase III studies. 
 
Cabozantinib -  
Cabozantinib is an oral tyrosine kinase inhibitor that blocks MET, vascular endothelial 
growth factor receptor 2 (VEGFR-2) as well as other tyrosine kinases including RET, KIT, 
AXL and FLT3 [79]. MET is overexpressed in bone metastases from solid tumours, such 
as prostate cancer, and is involved in proliferation, differentiation and migration of 
osteoblasts and osteoclasts [80]. In a phase II randomized discontinuation trial, 
cabozantinib produced a relevant PFS prolongation compared with placebo [81]. Of note, 
cabozantinib showed a partial or complete resolution of bone lesions in 56% and 19% of 
patients and 64% of patients who received analgesics experienced an improvement in 
pain intensity, while 46% stopped or reduced narcotics. Similarly, in a non-randomized 
phase II trial, cabozantinib produced pain palliation and pain relief in 42% and 57% of 
patients respectively [82]. Disappointingly, two phase III randomized trials produced 
negative results (Table C) [83,84]. In the COMET-1 trial, that compared cabozantinib 
versus prednisone in men with progressive mCRPC pre-treated with docetaxel, 
abiraterone and/or enzalutamide, cabozantinib improved PFS and bone scan response, 
but no OS improvement was observed [83]. In the COMET-2 trial, cabozantinib was 
compared versus mitoxantrone in men with progressive mCRPC, and the primary endpoint 
of pain palliation was not met [84]. 
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Dasatinib -  
SRC, a non-receptor protein tyrosine kinase, is a key signalling molecule in tumorigenesis 
and bone metabolism [85]. SRC signalling has a central role in tumour growth, invasion, 
metastasis, and is a mediator of osteoclast activity and function, involved in pathogenesis 
of prostate carcinoma bone metastases [86]. Dasatinib is a potent oral inhibitor of several 
tyrosine kinases including SRC, SFKs members and BCR-ABL [87]. In a phase I/II trial, 
dasatinib was evaluated in combination with docetaxel in chemotherapy-naïve or 
docetaxel pre-treated mCRPC patients [88]. Fourteen patients (30%) had disappearance 
of at least one bone lesion and 19 patients (41%) had stable bone scans. Most of the 
patients had decrease in urinary NTX and BALP (87% and 76%, respectively). In a phase 
II trial, conducted in mCRPC chemotherapy-naive patients [89], dasatinib showed again a 
significant reduction of urinary NTX and ALP. In the randomized phase III READY trial, 
dasatinib plus docetaxel was compared to docetaxel plus placebo in mCRPC 
chemotherapy-naive patients (Table C) [90], with OS as primary endpoint and SREs and 
pain palliation as secondary end points. Dasatinib failed to improve OS, while median time 
to first SRE was 31.1 months with placebo and not reached with dasatinib (HR 0.81, 
p=0.08). Reduction in pain intensity was not significantly different between arms.  
 
Anti-endothelin -  
Endothelins (ET-1, ET-2 and ET-3) are a family of small peptides with multiple roles 
including regulation of the vasomotor tone, nociception, hormone production and cellular 
proliferation [91]. ET-1 stimulates osteoblast activity and plays a key role in promoting  
prostate cancer growth and metastasis [92]. The activity of ET-1 is mediated by endothelin 
A receptor (ET-A) [93]. In preclinical models, endothelin receptor antagonists showed 
inhibition of  the development and progression of metastases [94].  
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Atrasentan is a potent, oral, selective ET-A antagonist that inhibits the osteoblast-
dependent formation of new bone induced by metastatic cancer cells [95]. In a phase II, 
placebo-controlled trial, atrasentan was tested in hormone refractory metastatic prostate 
cancer (HRPC) patients [96]. The primary endpoint was the rate of pain relief after 12 
weeks, that was not met. However, atrasentan 10 mg produced a statistically significant 
improvement in BPI, particularly the benefit was demostrated in pain interference with 
relations with other people (p=0.031) and in the worst pain in the last 24 hours (p=0.03). In 
another phase II trial in asymptomatic HRPC patients [94], markers of bone deposition and 
resorption were significantly reduced with atrasentan compared to placebo. A phase III 
randomized, placebo-controlled trial evaluating atrasentan in non-metastatic HRPC (Table 
C) did not meet the primary endpoint of delaying time to disease progression and did not 
show a significant improvement in time to first skeletal lesion, although atrasentan 
lengthened PSA doubling time (p=0.031) and slowed BALP increase (p<0.001) [97]. 
Zibotentan is an oral, selective ET-A antagonist, competing with ET-1 for receptor binding 
and therefore indirectly increasing pro-apoptotic signalling. Three trials (ENTHUSE) 
evaluated zibotentan in CRPC patients (Table C) [98-100]. Disappointingly, in these trials 
there was no significant improvement either in OS, the primary endpoint, or in secondary 
endpoints, including time to pain progression and pain response.  
 
Cathepsin K inhibitors  
 
Cathepsin K is a cysteine protease, expressed in osteoclasts and various type of cancers 
[101]. It plays a key role in osteoclast-mediated bone resorption and promotes tumor cells 
invasion [102]. Cathepsin K inhibitors have been studied for post-menopausal 
osteoporosis and bone metastatic disease [103]. Odanacatib, a cathepsin K inhibitor, has 
been evaluated in a randomized, double blind trial in order to assess the efficacy and 
safety in reducing markers of bone resorption in bone metastatic breast cancer patients 
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[104]. Forty-three patients were randomized to oral odanacatib 5 mg daily for 4 weeks or 
intravenous ZA 4 mg given once at study initiation. The study showed that odanacatib 
reduced uNTx similarly to ZA after 4 weeks of treatment [104].Two phase III clinical trials 
were planned in order to evaluate its efficacy and safety in prolonging time to first bone 
metastasis in CRPC patients (NCT00691899) and in reducing risk of bone metastases in 
women with breast cancer (NCT00692458). Unfortunately, these studies were closed 
before starting accrual [105]. Further clinical trials are needed in order to obtain more 
clinical informations. 
 
Aflibercept  
 
Aflibercept is an anti-angiogenic agent with high affinity to the isoform VEGF-A, it also 
binds VEGF-B and platelet-derived growth factors PlGF1 and PlGF2 [106]. A recent phase 
III, randomized, double-blind placebo-controlled trial (VENICE) has evaluated docetaxel 
plus aflibercept vs docetaxel plus placebo in 1224 mCRPC patients [107]. The primary 
endpoint was OS; secondary endpoints included PFS, PSA-PFS, time to first SRE and 
pain-PFS. Aflibercept has not met its primary endpoint (22.1 months vs 21.1 months; 
p=0.38). There were not differences in terms of secondary end-points, in particular median 
time to first SRE was 15.3 months in aflibercept group vs 15.0 months in placebo group 
(p=0.31). 
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CONCLUSIONS  
Recently, a better understanding of mechanisms associated with bone metastatic disease 
in prostate cancer and, more specifically, the crucial role of cross-talk between tumor cells 
and bone micro-environment in metastatic progression provided the basis for the 
development of new effective bone-targeted therapies.  
There is no question that prostate cancer cells have a strong bone tropism, and their 
dissemination into the bone alters the equilibrium between osteoclasts and osteoblasts. 
Although bone lesions secondary to prostate carcinoma are mainly characterized by 
aberrant osteoblast activation, osteolysis is common and is responsible of increased 
incidence of SREs that are dramatic clinical events, able to decrease QoL, autonomy and 
survival of CRPC patients.  
Abnormal osteoclast activity is the rationale for the administration of potent osteolysis 
inhibitors, such as zoledronic acid and denosumab. These agents reduce the burden of 
bone metastatic disease, although this benefit does not translate in an improvement in 
survival.  
Recently, a new treatment opportunity for patients with prostate cancer and bone 
metastases is represented by radium-223. Notably, this α-emitter, when used in men with 
CRPC and bone metastases, not only showed efficacy in preventing symptomatic skeletal 
events, but it was the first bone-targeted therapy associated with a significant OS 
improvement.  
Additionally, in the last five years, highly effective new systemic agents have significantly 
changed the treatment landscape of CRPC patients, improving their life expectancy [12]. 
Some of these therapies also documented efficacy in delaying SRE and improving bone 
pain. Trials testing the concomitant administration of radium-223 with abiraterone 
(NCT02043678), enzalutamide (NCT02194842) and docetaxel (NCT01106352) are 
ongoing. Results of these studies will help to better understand how to combine systemic 
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new agents with bone-targeted therapies, in order to effectively interfere with the “seed” 
and with the “soil” at the same time. 
29 
 
Figure legends 
Figure A. Mechanisms of shift from hematopoietic stem cell niche to “onco-niche”. 
A) Hematopoietic stem cell into the bone marrow is localized in the hematopoietic stem 
cell niche in connection with osteoblasts through SDF-1/CXCR4 pathway. Prostatic tumor 
cells are able to compete with hematopoietic stem cell for the place in the bone marrow 
using SDF-1/CXCR4 axis, favoring the formation of “onco-niche.  
B) In the “onco-niche”, cancer cell may remain in a state of dormancy or may start to 
colonize and invade bone.  
 
Figure B. Pathogenesis of “vicious cycle” that underpin osteoblastic bone metastases 
from prostate carcinoma.  
A) In the early phase of metastatic colonization osteolysis predominates due to production 
of transforming growth factor β1 (TGF β1), parathyroid-hormone-related peptide (PTHrP) 
and interleukin 6 (IL-6). These factors activate the receptor activator nuclear kappa B 
(RANK)/RANK ligand (RANKL) pathway, which is responsible of bone resorption 
stimulation. 
B) The increase of osteolysis causes the release from bone matrix of growth factors and 
cytokines responsible for neoplastic proliferation.  
C) In the next phase of skeletal colonization bone neoapposition become dominant due to 
growth factors released by cancer cells and from bone matrix, such as basic fibroblast 
growth factor (bFGF), bone morphogenic proteins (BMPs), endothelin-1 (ET-1), tumour 
growth factor b1 (TGFb1) and insulin-like growth factor 1 (IGF-1), able to stimulate 
osteoblasts activity.  
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